Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

38 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-11-30

Study Completion Date

2008-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study hypothesis: Valsartan as an angiotensin II receptor blocker treatment has beneficial effects on both midwall mechanics and myocardial functions in hypertensive patients with Left ventricular hypertrophy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

NCT01912534

Hypertrophic Cardiomyopathy

COMPLETED PHASE2

Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH

NCT03180593

Hypertension Complicated Hypertrophy, Left Ventricular Blood Pressure

COMPLETED PHASE4

Valsartan Intensified Primary Care Reduction of Blood Pressure Study

NCT00902304

Hypertension

COMPLETED PHASE4

A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg

NCT00241137

Hypertension

COMPLETED PHASE3

The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure

NCT00241098

Hypertension Congestive Heart Failure

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Left Ventricular Hypertrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Valsartan treatment

Group Type EXPERIMENTAL

valsartan

Intervention Type DRUG

80/160 mg dosage of valsartan or 160+12,5 mg valsartan+hydrochlorothiazide combination, once a day, for six months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

valsartan

80/160 mg dosage of valsartan or 160+12,5 mg valsartan+hydrochlorothiazide combination, once a day, for six months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Diovan 80 mg Diovan 160 mg Co-diovan 160/12,5 mg

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* hypertension with left ventricular hypertrophy

Exclusion Criteria

* clinical or laboratory evidence of secondary hypertension
* heart failure
* ischemic heart disease
* valvular heart disease
* arrhythmias
* peripheral vascular disease
* chronic obstructive pulmonary disease
* neurologic disorders
* diabetes mellitus
* renal dysfunction
* notable systemic disease

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No